HomeInsightsStock Comparison

Astrazeneca Pharma India Ltd vs Glenmark Pharmaceuticals Ltd Stock Comparison

Astrazeneca Pharma India Ltd vs Glenmark Pharmaceuticals Ltd Stock Comparison

Last Updated on: Aug 21, 2025

Key Highlights

  • The Latest Trading Price of Astrazeneca Pharma India Ltd is ₹ 8397 as of 21 Aug 15:30.
  • The P/E Ratio of Astrazeneca Pharma India Ltd changed from 0 on March 2020 to 0 on March 2024 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Glenmark Pharmaceuticals Ltd changed from 7.5 on March 2020 to 0 on March 2024 . This represents a CAGR of -100.00% over 5 years.
  • The Market Cap of Astrazeneca Pharma India Ltd changed from ₹ 0 crore on March 2020 to ₹ 0 crore on March 2024 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Glenmark Pharmaceuticals Ltd changed from ₹ 5814 crore on March 2020 to ₹ 27019 crore on March 2024 . This represents a CAGR of 35.97% over 5 years.
  • The revenue of Astrazeneca Pharma India Ltd for the Jun '25 is ₹ 0 crore as compare to the Mar '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Glenmark Pharmaceuticals Ltd for the Jun '25 is ₹ 3290 crore as compare to the Mar '25 revenue of ₹ 3267 crore. This represent the growth of 0.7%.
  • The ebitda of Astrazeneca Pharma India Ltd for the Jun '25 is ₹ 0 crore as compare to the Mar '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Glenmark Pharmaceuticals Ltd for the Jun '25 is ₹ 283.73 crore as compare to the Mar '25 ebitda of ₹ 199.89 crore. This represent the growth of 41.94%.
  • The net profit of Astrazeneca Pharma India Ltd changed from ₹ 0 crore to ₹ 0 crore over 9 quarters. This represents a CAGR of 0.0% The net profit of Glenmark Pharmaceuticals Ltd changed from ₹ 173.13 crore to ₹ 46.97 crore over 9 quarters. This represents a CAGR of -44.00% .
  • The Dividend Payout of Astrazeneca Pharma India Ltd changed from 3.46 % on March 2020 to 69.12 % on March 2025 . This represents a CAGR of 64.72% over 6 yearsThe Dividend Payout of Glenmark Pharmaceuticals Ltd changed from 5.21 % on March 2020 to 0 % on March 2025 . This represents a CAGR of -100.00% over 6 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Astrazeneca Pharma India Ltd

  • AstraZeneca Pharma India Limited (APIL) was incorporated on July 11, 1979.
  • The Company is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and co-ordinates clinical trial services with an overseas group company.
  • The major therapy areas where the company operates are Onocology, Alimentary & Metabolism, Cardio Vascular, Renal, Diabetes, Respiratory and Oncology. AstraZeneca Pharma India, formerly known as Astra-IDL (AIL), was an erstwhile joint venture of Astra Zeneca, UK and Hinduja controlled IDL. Astra Pharmaceuticals AB, Sweden acquired all of the 1287500 equity shares in the Company of IDL, representing 25.75% of the Company's issued and paid up equity share capital.
  • Consequently, the Company became a subsidiary of Astra, which is a direct wholly owned subsidiary of Astra AB, Sweden (now known as AstraZeneca Pharmaceuticals AB Sweden) and an indirect wholly owned subsidiary of AstraZeneca Plc, the Group parent Company.

About Glenmark Pharmaceuticals Ltd

  • Glenmark Pharmaceuticals Limited was incorporated on November 18, 1977.
  • The Company is actively involved in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity).
  • It is engaged in the business of development, manufacture and marketing of pharmaceutical products both formulation and active pharmaceuticals ingredients to regulated and semi-regulated markets.
  • The Company's research and development facilities are located at Mahape, Sinnar and Taloja and manufacturing facilities are located at Nasik, Colvale, Baddi, Nalagarh, Sikkim, Indore and Aurangabad in India. The company has several molecules in various stages of pre-clinical and clinical development primarily focused in the areas of Oncology, Respiratory and Dermatology.
  • Its branded generics business has a significant presence in markets across emerging economies including India.

Astrazeneca Pharma India Ltd News Hub

News

AstraZeneca Pharma to launch Eculizumab (Soliris) in India

 AstraZeneca Pharma India announced that it will launch Eculizumab (Soliris) in August 202...

Read more

06 Aug 2025 15:43

News

Astrazeneca Pharma India to convene AGM

Astrazeneca Pharma India announced that the Annual General Meeting(AGM) of the company wil...

Read more

29 Jul 2025 12:58

News

Astrazeneca Pharma India schedules board meeting

Astrazeneca Pharma India will hold a meeting of the Board of Directors of the Company on 1...

Read more

25 Jul 2025 11:10

News

AstraZeneca Pharma gets CDSCO approval to import Durvalumab Solution

Through this approval, Durvalumab in combination with carboplatin and paclitaxel is indica...

Read more

02 Jul 2025 10:26

News

Astrazeneca Pharma India Ltd leads losers in 'A' group

Orient Cement Ltd, India Cements Ltd, Concord Biotech Ltd and ERIS Lifesciences Ltd are am...

Read more

20 Jun 2025 15:00

News

AstraZeneca Pharma slides as MD Sanjeev Panchal steps down; Praveen Rao Akkinepally to take charge

Panchal is set to transition to a global role within the AstraZeneca Group, based in Gaith...

Read more

10 Jun 2025 09:49

Glenmark Pharmaceuticals Ltd News Hub

News

Glenmark USA to launch Micafungin for Injection 50 mg/vial and 100 mg/vial

Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the upcoming launch of Micafungin ...

Read more

19 Aug 2025 10:07

News

Glenmark Pharma's US arm to launch Micafungin injection in the US market

The product is bioequivalent and therapeutically equivalent to the reference listed drug M...

Read more

19 Aug 2025 12:11

News

Glenmark Pharmaceuticals announces board meeting date

Glenmark Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 1...

Read more

05 Aug 2025 18:06

News

Glenmark Pharmaceuticals Ltd spurts 1.22%, up for third straight session

Glenmark Pharmaceuticals Ltd rose for a third straight session today. The stock is quoting...

Read more

28 Jul 2025 13:05

News

Glenmark Pharmaceuticals receives revision in outlook on LT bank facilities

India Ratings and Research (Ind-Ra) has revised the Outlook on Glenmark Pharmaceuticals' (...

Read more

23 Jul 2025 18:35

News

Glenmark Pharmaceuticals Ltd up for five straight sessions

Glenmark Pharmaceuticals Ltd rose for a fifth straight session today. The stock is quoting...

Read more

16 Jul 2025 13:00

SWOT Analysis Of Glenmark Pharmaceuticals Ltd

Strength

4

S

Weakness

2

W

Opportunity

1

O

Threats

1

T

BlinkX Score for Astrazeneca Pharma India Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Glenmark Pharmaceuticals Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Astrazeneca Pharma India Ltd and Glenmark Pharmaceuticals Ltd

Which company has a larger market capitalization, Astrazeneca Pharma India Ltd or Glenmark Pharmaceuticals Ltd?

Market cap of Astrazeneca Pharma India Ltd is 20,993 Cr while Market cap of Glenmark Pharmaceuticals Ltd is 54,792 Cr

What are the key factors driving the stock performance of Astrazeneca Pharma India Ltd and Glenmark Pharmaceuticals Ltd?

The stock performance of Astrazeneca Pharma India Ltd and Glenmark Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Astrazeneca Pharma India Ltd and Glenmark Pharmaceuticals Ltd?

As of August 21, 2025, the Astrazeneca Pharma India Ltd stock price is INR ₹8397.35. On the other hand, Glenmark Pharmaceuticals Ltd stock price is INR ₹1941.6.

How do dividend payouts of Astrazeneca Pharma India Ltd and Glenmark Pharmaceuticals Ltd compare?

To compare the dividend payouts of Astrazeneca Pharma India Ltd and Glenmark Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions